Status:
COMPLETED
Oxytocin and Sleeve Gastrectomy
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Obesity, Morbid
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Morbid obesity has become a common condition and there is no effective drug that is able to induce a sustained weight loss. Currently bariatric surgery remains the only effective means that is able to...
Eligibility Criteria
Inclusion
- Women aged 18-65, pre-menopausal,
- able to read and understand the written informed consent,
- with a BMI \> 40 or 35
- with at least one obesity linked comorbidity among blood hypertension,
- type 2 diabetes,
- sleep apnea syndrome,
- invalidating arthritis,
- indication for sleeve gastrectomy
- accepted by the multidisciplinary committee and the CPAM (local health care system agency),
- affiliation to the Fre,nch health care system,
- signature of the informed consent.
Exclusion
- Post-menopausal women,
- any other bariatric procedure that sleeve gastrectomy, history of any other bariatric procedure,
- pregnancy,
- age less than 18 years under, under guardianship
- Patients undergoing any other procedure that the planned sleeve gastrectomy or undergoing a second bariatric procedure for a complications during the 6 months follow-up.
Key Trial Info
Start Date :
November 24 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05307133
Start Date
November 24 2022
End Date
March 4 2025
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, Alpes-maritimes, France, 06001